AcelRx Pharmaceuticals (NASDAQ:ACRX)’s share price was up 6.7% during mid-day trading on Monday . The company traded as high as $2.45 and last traded at $2.40. Approximately 1,012,982 shares traded hands during trading, an increase of 130% from the average daily volume of 439,875 shares. The stock had previously closed at $2.25.
Separately, Zacks Investment Research downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $4.92.
The company has a debt-to-equity ratio of -0.31, a current ratio of 4.64 and a quick ratio of 4.57. The stock has a market capitalization of $114.52, a PE ratio of -2.18 and a beta of 2.41.
A hedge fund recently raised its stake in AcelRx Pharmaceuticals stock. Geller Family Office Services LLC lifted its stake in shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) by 175.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 275,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 175,000 shares during the quarter. AcelRx Pharmaceuticals makes up 0.3% of Geller Family Office Services LLC’s holdings, making the stock its 17th biggest holding. Geller Family Office Services LLC owned about 0.55% of AcelRx Pharmaceuticals worth $557,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.20% of the company’s stock.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.